Rubicon Research has incorporated a wholly owned subsidiary -- AdvaGen S A Company in the Kingdom of Saudi Arabia on January 13, 2026. The AdvaGen S A Company will deal in pharmaceutical products. The cost of subscription of AdvaGen S A Company’s shares was 1 lakh Saudi Riyal.
Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of speciality products and drug-device combination products targeting regulated markets and in particular the United States.
